Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.25 USD | -1.75% | -8.20% | -29.25% |
May. 15 | Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA | CI |
May. 15 | Lumos Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Financials (USD)
Sales 2024 * | 8.75M | Sales 2025 * | 8.66M | Capitalization | 18.26M |
---|---|---|---|---|---|
Net income 2024 * | -40M | Net income 2025 * | -40M | EV / Sales 2024 * | 2.09 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 2.11 x |
P/E ratio 2024 * |
-0.69
x | P/E ratio 2025 * |
-1.27
x | Employees | 33 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 64.97% |
Latest transcript on Lumos Pharma, Inc.
1 day | -1.75% | ||
1 week | -8.20% | ||
1 month | -19.93% | ||
3 months | -26.23% | ||
6 months | -21.33% | ||
Current year | -29.25% |
Managers | Title | Age | Since |
---|---|---|---|
Richard Hawkins
CEO | Chief Executive Officer | 75 | 10-08-31 |
Lori Lawley
DFI | Director of Finance/CFO | 40 | 20-02-29 |
John McKew
PSD | President | 59 | 15-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Lota Zoth
BRD | Director/Board Member | 64 | 12-10-31 |
Richard Hawkins
CEO | Chief Executive Officer | 75 | 10-08-31 |
Kevin Lalande
BRD | Director/Board Member | 51 | 13-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 2.25 | -1.75% | 13,215 |
24-05-30 | 2.29 | -0.87% | 20,757 |
24-05-29 | 2.31 | -.--% | 6,986 |
24-05-28 | 2.31 | -5.75% | 22,403 |
24-05-24 | 2.451 | -1.96% | 65,546 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-29.25% | 18.26M | |
+43.36% | 54.64B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- LUMO Stock